Qualysec

BLOG

Understanding FDA Classification of Software as a Medical Device (SaMD)

Pabitra Kumar Sahoo

Pabitra Kumar Sahoo

Updated On: March 6, 2025

chandan

Chandan Kumar Sahoo

August 29, 2024

Understanding FDA Classification of Software as a Medical Device
Table of Contents

The intersection of software and healthcare has revolutionized the way medical care is delivered. With increasing advancements, a growing number of software applications are playing critical roles in diagnosing, treating, and monitoring patients. But did you know that certain software applications are categorized as Software as a Medical Device FDA by the U.S. Food and Drug Administration? If your software falls under this classification, you need to know what that means and what’s required for compliance.

This blog will guide you through understanding what Software as a Medical Device (SaMD) is, the FDA’s classification system, and what this means for software developers and healthcare innovators. By the end, you’ll have a solid grasp of how SaMD classification impacts regulatory requirements and market access.

What Is Software as a Medical Device (SaMD)?

Let’s break it down. Software as a Medical Device (SaMD) refers to software that is intended to perform one or more medical purposes without being part of a physical hardware medical device. For example, a mobile app that analyzes medical imaging to diagnose conditions like cancer or heart disease would qualify as SaMD.

The International Medical Device Regulators Forum (IMDRF), a global consortium of regulators, offers a formal definition of SaMD as “software intended to be used for one or more medical purposes that perform those purposes without being part of a hardware medical device.” The FDA aligns its regulatory framework with this definition to streamline processes internationally.

Real-World Examples of SaMD

To better understand, here are some examples:

  1. Diagnostic Tools: Software that uses AI to detect diseases in radiology scans or lab results (example – identifying abnormalities in X-rays).
  2. Monitoring Systems: Mobile apps that track patient vitals, such as heart rate and blood glucose levels, then provide actionable recommendations.
  3. Chronic Disease Management: Software to help patients manage conditions like diabetes through medication reminders and personalized health insights.

Why Does the FDA Classify SaMD?

The Software as a Medical Device FDA classification ensures that SaMD is safe, effective, and reliable. This classification helps maintain quality standards, which is critical for protecting public health. SaMD products, like other medical devices, can pose risks if they malfunction or produce inaccurate results, which underscores the need for oversight.

While SaMD creates groundbreaking opportunities in healthcare, misreporting, glitches, or algorithm biases have the potential to endanger patients. The FDA’s classification system facilitates risk-based regulation aimed at mitigating these issues.

Related Content: FDA Cybersecurity Guidelines for Medical Devices 2025

How Does the FDA Classify SaMD?

The FDA employs a risk-based approach to classify SaMD based on its intended use and risk profile to the patient. SaMD classification relies heavily on understanding – the intended purpose of the software and the potential impact on the patient or user if the software fails.

The 3 FDA Classifications for SaMD

The FDA classifies SaMD into three categories – Class I, Class II, and Class III, based on intended use and level of risk to the patient. Below, we’ll explore each classification, its criteria, and examples to help you understand the differences. 

 

FDA Classifications for SaMD

1. Class I SaMD – Low Risk

Class I SaMD encompasses devices with the lowest risk to patients. These are typically tools that support general health management without making critical medical decisions. 

 

Criteria for Class I: 

  • The software poses minimal risk to the patient if it fails to perform as intended. 
  • It primarily collects or analyzes data without providing diagnostic results. 

Examples of Class I SaMD: 

  • Fitness apps that track physical activity levels, such as step counters. 
  • Health monitoring software that logs blood pressure or heart rate trends. 
  • Apps providing general wellness tips without specific medical guidance. 

Regulatory Requirements: 

Most Class I SaMD products are exempt from premarket notification (510 [k]). However, developers must still adhere to basic FDA regulations, including proper labeling and quality system requirements. 

2. Class II SaMD – Moderate Risk 

Most SaMD falls into Class II, as this category includes software that supports clinical decision-making but does not directly intervene or treat patients. 

 

Criteria for Class II: 

  • A failure in the software could pose a moderate risk to the patient. 
  • The software provides diagnostic insights or recommendations that a medical professional uses alongside their judgment. 

Examples of Class II SaMD: 

  • Radiology image processing software that highlights potential abnormalities for radiologists to review. 
  • Apps that monitor glucose levels for diabetic patients and provide alerts. 
  • Clinical decision support software that suggests appropriate drug dosages based on patient data. 

Regulatory Requirements: 

Class II products require premarket notification in the form of a 510(k) submission. This demonstrates that the software is substantially equivalent to an already approved device on the market, ensuring its safety and effectiveness. 

3. Class III SaMD – High Risk 

Class III SaMD represents the highest risk level. These are devices that provide life-saving or life-sustaining functionalities and significantly influence patient outcomes. The FDA requires rigorous testing and approval for these products. 

 

Criteria for Class III: 

  • The software directly diagnoses, prevents, or treats life-threatening conditions. 
  • A failure or malfunction could have severe consequences for the patient. 

Examples of Class III SaMD: 

  • AI systems that autonomously diagnose cancer without human intervention. 
  • Software that controls the delivery of insulin for diabetic patients. 
  • Emergency response apps that monitor critical health metrics in real time and alert medical teams. 

Regulatory Requirements: 

Class III products must undergo the FDA’s Premarket Approval (PMA) process, the most stringent regulatory pathway. Manufacturers must provide detailed clinical data to demonstrate the software’s safety, efficacy, and reliability. 

You might like to explore: FDA Penetration Testing: Why It’s Vital for 510(k) Submission?

 

Latest Penetration Testing Report
Pentesting Buyer Guide

SaMD Regulatory Overview: Key Steps for FDA Approval

If you’re developing SaMD, here’s how to successfully navigate the FDA approval process:

  1. Determine Classification: Research your product’s intended use and compare it to FDA guidelines to identify its classification.
  2. Provide Adequate Documentation: Include a comprehensive summary of the device’s intended use, technical specifications, risk analyses, and testing processes.
  3. Conduct Clinical Validation: Prove the software’s accuracy and reliability for high-risk Class II and III SaMDs through clinical trials or performance studies.
  4. Submit Premarket Application: Whether it’s through the 510(k) notification process or PMA, upload all required compliance information to the FDA.
  5. Post-market Surveillance: Continue monitoring your SaMD after approval to ensure its safety and effectiveness in real-world use.

Benefits of FDA-Compliant SaMD

Meeting FDA requirements isn’t just about jumping through hoops. It offers developers numerous advantages:

  • Market Access: FDA approval or clearance grants access to the U.S. market, one of the largest healthcare markets globally.
  • User Trust: Compliance tells users they can confidently rely on your software.
  • Competitive Edge: Having a robust regulatory pathway in place can differentiate your product in an increasingly crowded market.

According to market reports, the global SaMD market is projected to grow from $5.4 billion in 2023 to $10.9 billion by 2028. Regulatory clarity from the FDA plays a significant role in accelerating innovation in this space.

 

Talk to our Cybersecurity Expert to discuss your specific needs and how we can help your business.

Final Thoughts!

Proceeding for Software as a Medical Device FDA classification may seem complex, but it’s an essential step toward transforming healthcare through innovation. Whether you’re developing low-risk wellness apps or advanced diagnostic tools, ensuring compliance not only protects patient health but opens doors to business growth and international recognition.

If you’re unsure where to start, prioritize understanding risk levels and regulatory requirements. Engage with compliance experts to streamline your pathway to approval and focus on designing SaMD that delivers meaningful impact while adhering to the highest safety standards.

By aligning your SaMD development process with FDA expectations, you’ll not only meet regulatory benchmarks but also play a key role in revolutionizing modern medicine. Contact Qualysec for more information.

Qualysec Pentest is built by the team of experts that helped secure Mircosoft, Adobe, Facebook, and Buffer

Pabitra Kumar Sahoo

Pabitra Kumar Sahoo

CEO and Founder

Pabitra Sahoo is a cybersecurity expert and researcher, specializing in penetration testing. He is also an excellent content creator and has published many informative content based on cybersecurity. His content has been appreciated and shared on various platforms including social media and news forums. He is also an influencer and motivator for following the latest cybersecurity practices. Currently, Pabitra is focused on enhancing and educating the security of IoT and AI/ML products and services.

Leave a Reply

Your email address will not be published.

Save my name, email, and website in this browser for the next time I comment.

0 Comments

No comments yet.

Chandan Kumar Sahoo

CEO and Founder

Chandan is the driving force behind Qualysec, bringing over 8 years of hands-on experience in the cybersecurity field to the table. As the founder and CEO of Qualysec, Chandan has steered our company to become a leader in penetration testing. His keen eye for quality and his innovative approach have set us apart in a competitive industry. Chandan's vision goes beyond just running a successful business - he's on a mission to put Qualysec, and India, on the global cybersecurity map.

3 Comments

emurmur

John Smith

Posted on 31st May 2024

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut et massa mi. Aliquam in hendrerit urna. Pellentesque sit amet sapien fringilla, mattis ligula consectetur, ultrices mauris. Maecenas vitae mattis tellus. Nullam quis imperdiet augue.

    Get a Quote

    Pentesting Buying Guide, Perfect pentesting guide

    Subscribe to Newsletter

    Scroll to Top
    Pabitra Kumar Sahoo

    Pabitra Kumar Sahoo

    COO & Cybersecurity Expert

    “By filling out this form, you can take the first step towards securing your business, During the call, we will discuss your specific security needs and whether our services are a good fit for your business”

    Get a quote

    For Free Consultation

    Pabitra Kumar Sahoo

    Pabitra Kumar Sahoo

    COO & Cybersecurity Expert